WESTLAKE VILLAGE, Calif., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology, today announced it will present new data from the previously announced Phase 2 studies of ARQ-151 (topical roflumilast cream) in chronic plaque psoriasis and atopic dermatitis at the European Academy of Dermatology and Venereology (EADV) Virtual Congress (EADV Virtual), the Society of Dermatology Physician Assistants (SPDA) Digital 2020 conference, and the virtual 2020 Fall Clinical Dermatology Conference.
News Ticker
- [ March 26, 2023 ] Quality Control Lead, Global Quality Control Microbiology – Kite Pharma – Santa Monica, CA Los Angeles Biotech Jobs
- [ March 26, 2023 ] Aadi Bioscience Presents Clinical Data from PRECISION 1 and AMPECT Trials at the Society of Gynecological Oncology (SGO) Annual Meeting on Women’s Cancer Los Angeles Biotech News
- [ March 26, 2023 ] Research Associate – Aptitude Medical – Santa Barbara, CA Los Angeles Biotech Jobs
- [ March 26, 2023 ] Lab Manager (Research Program Administrator) – CEDARS-SINAI – Los Angeles, CA Los Angeles Biotech Jobs
- [ March 26, 2023 ] Sr Account Director, Business Development – (GMP Labs) – West Coast Region – Thermo Fisher Scientific – Los Angeles, CA Los Angeles Biotech Jobs
Copyright © 2021 Biotech Networks, LLC
